TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL‐1

Abstract Platinum resistance remains a major contributor to the poor prognosis of ovarian cancer. Anti‐apoptotic protein myeloid cell leukemia‐1 (MCL‐1) has emerged as a promising target for overcoming drug resistance, but different cancer cells utilize distinct protein degradation pathways to alter MCL‐1 level. We systematically investigated E3 ligases to identify novel candidates that mediate platinum resistance in ovarian cancer. Transcription Elongation Factor B (TCEB3) has been identified as a novel E3 ligase recognition subunit that targets MCL‐1 in the cytoplasm during platinum treatment other than its traditional function of targeting the Pol II in the nuclear compartment. TCEB3 expression is downregulated in platinum‐resistant cell lines and this low expression is associated with poor prognosis. The ubiquitination of MCL‐1 induced by TCEB3 leads to cell death in ovarian cancer. Moreover, platinum treatment increased the cytoplasm proportion of TCEB3, and the cytoplasm localization of TCEB3 is important for its targeting of MCL‐1. This study emphasizes the dual function of TCEB3 in homeostasis maintenance and in cell fate determination under different conditions, and provides a new insight into drug resistance in ovarian cancer.